FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Quince Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Quince Therapeutics, Inc. (QNCX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisQNCX
QNCX
Quince Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
QNCX
Home🔹Stocks🔹Quince Therapeutics, Inc.

Quince Therapeutics, Inc.

QNCX•NASDAQ

Quince Therapeutics, Inc.

QNCX•NASDAQ
Market cap
$5.15M
Sentiment

Your view on QNCX

Mkt Cap
$5.15M
Sentiment
Your view
QNCX
Quince Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
QNCX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Quince Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Dirk Thye
Headquarters
601 Gateway Blvd, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Dirk Thye
Headquarters
601 Gateway Blvd, South San Francisco, CA, US
Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News